Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why ImmunoGen Inc. Shares Took Flight

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of ImmunoGen (NASDAQ: IMGN  ) , a biopharmaceutical company focused on developing therapies to fight cancer, advanced as much as 15% after research firm Canaccord Genuity initiated coverage on the company.

So what: Before the opening bell rang, Canaccord Genuity issued a buy rating on ImmunoGen with a $20 price target, implying upside potential of 56% based on yesterday's closing price. According to Canaccord, it believes that ImmunoGen and Roche's (NASDAQOTH: RHHBY  )  drug, Kadcyla -- a targeted antibody payload therapy that piggybacks a toxin onto an antibody and delivers that toxin to targeted cancer cells -- will be successful in a late-stage trial in treating HER2-positive metastatic breast cancer. Canaccord anticipates positive top-line results in the second half of this year and sees north of a $7 billion opportunity in this HER2-positive adjuvant breast cancer space. Although Canaccord isn't anticipating a huge revenue impact immediately from Kadcyla, it does see revenue growth accelerating nicely over time.

Now what: As per the norm, it's never a good idea to put too much credence into the ratings of Wall Street analysts as they're often very short-term drivers of a stock's share price. But this is one of those rare cases where I agree wholeheartedly with Canaccord, so it's not exactly affecting or altering my investment thesis.

I firmly believe that ImmunoGen's TAP technology, and its peers' antibody-drug conjugate technology, offers biopharmaceuticals a more focused way of attacking cancer cells and improving patient quality of life and overall survival. ImmunoGen has a deep pipeline of cancer therapeutics as well as a number of key partnerships in the space lending itself plenty of opportunities to hit a home run. It could be some time before ImmunoGen sees steady cash flow from its hard work (i.e., expect ongoing losses in the meantime), but the viability of its proprietary TAP technology is very promising. I would certainly suggest biotech-savvy investors add ImmunoGen to your watchlist moving forward.

ImmunoGen may be soaring today, but it'll likely be hard-pressed to keep pace with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2917880, ~/Articles/ArticleHandler.aspx, 8/29/2015 10:57:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 13 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
IMGN $14.28 Down +0.00 +0.00%
ImmunoGen CAPS Rating: ***
RHHBY $34.16 Down -0.69 -1.98%
Roche Holding Ltd.… CAPS Rating: *****